Adverse health outcomes and global quality of life in long-term testicular cancer survivors: a longitudinal 30-year perspective

Fosså, S.D.; Haugnes, H.S.; Dahl, A.A.; Kiserud, C.E.; Fosså, A.; Skalleberg, J.; Myklebust, T.Å.

doi:10.1016/j.annonc.2023.09.3101

Cited by 3 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Understanding the late effects of cancer therapy has become increasingly important as the 5-year survival rate for the pediatric cancer population currently exceeds 80% (1,2). Platinum-based chemotherapy agents such as cisplatin and carboplatin are routinely used in treatment, and although they continue to be highly effective chemotherapy agents, they are also associated with the development of significant late effects, among which include ototoxic hearing loss and decreased quality of life (QOL) (3)(4)(5)(6). There is evidence to suggest that the development of ototoxic hearing loss and decreased QOL share similar risk factors; such as, younger age at diagnosis, central nervous system (CNS) malignancies, and exposure to cranial radiation, making it difficult to assess whether they are independent outcomes (7,8).…”

Section: Introductionmentioning

confidence: 99%

Assessing quality of life in childhood cancer survivors at risk for hearing loss: a comparison of HEAR-QL and PROMIS measures

Spence,

L’Hotta,

Hayashi

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundChildhood cancer survivors (CCS) exposed to platinum chemotherapy are at an increased risk of developing hearing loss and reporting decreased quality of life (QOL). This study compared two QOL measures; one developed for children with hearing loss, The Hearing Environments and Refection on Quality of Life (HEAR-QL), and one validated in CCS, the Patient-Reported Outcomes Measurement Information System (PROMIS), to assess their ability to evaluate QOL deficits in this population.MethodsSubject eligibility were restricted to CCS exposed to platinum-based chemotherapy but who were free of known risk factors for cognitive impairment, (non-central nervous system tumor, no cranial radiation, or intrathecal chemotherapy). Participants had to be between 8-17 years, have completed anti-cancer therapy for at least 6 months, and have an audiogram within 1 year, Participants completed the HEAR-QL-26 (7-12 years) or the HEAR-QL-28 (13-18 years) and the PROMIS. Independent samples and/or one sample T-tests were utilized to compare participants with normal hearing and hearing loss, and to compare outcome measures to normative HEAR-QL and PROMIS data. Non-parametric correlations were utilized to evaluate the relationship between QOL and demographic and medical variables, and QOL and severity of hearing loss.ResultsFifty-four CCS were evaluable. The mean age was 12.0 years. Twenty-eight participants (51.9%) received cisplatin, 30 (55.6%) carboplatin, and 4 (7.4%) received both. Twenty participants (37%) demonstrated hearing loss. Participants with hearing loss scored significantly lower on the HEAR-QL than those with normal hearing (mean: 70.3, SD: 21.7, vs mean: 88.0, SD: 9.3, p =.004 for the HEAR-QL-26; mean: 84.7, SD: 10.2 vs mean: 94.8, SD: 3.4, p =.040 for the HEAR-QL-28). Participants with normal hearing scored significantly lower on the HEAR-QL-26 than the normative mean (mean: 88, SD: 9.3, normative mean: 98, SD: 5, p =.000). The PROMIS failed to identify any differences in QOL between participants based on hearing status, or when compared to the normative mean.ConclusionThe HEAR-QL was more sensitive than the PROMIS in identifying QOL deficits in CCS at risk for hearing loss. The HEAR-QL should be considered in studies seeking to improve the QOL of CCS with hearing loss.

show abstract

Section: Introductionmentioning

confidence: 99%

Assessing quality of life in childhood cancer survivors at risk for hearing loss: a comparison of HEAR-QL and PROMIS measures

Spence,

L’Hotta,

Hayashi

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Favorable long-term Health Related Quality of Life in cured survivors of testicular cancer management. So, what now?

D’Souza,

King,

Nappi

et al. 2023

Annals of Oncology

View full text Add to dashboard Cite

Malignant ovarian and testicular germ cell tumors: Common characteristics but different prognoses

Sköld,

Jansson,

Glimelius

2024

J Intern Med

View full text Add to dashboard Cite

Both ovarian and testicular germ cell tumors (GCTs) arise from the primordial germ cell and share many similarities. Both malignancies affect mainly young patients, show remarkable responsiveness to cisplatin‐based therapy, and have an excellent prognosis, which also highlights the importance of minimizing long‐term side effects. However, certain differences can be noted: The spreading of the disease differs, and the staging system and treatment recommendations are dissimilar. Moreover, the prognosis for ovarian GCTs is significantly inferior to that for testicular cancer, as exemplified in this review comparing the survival in Swedish patients diagnosed with testicular (1995–2022) and ovarian (1990–2018) GCTs. The 5‐year overall survival in ovarian GCTs was 85.2%, versus 98.2% for testicular GCTs. How can this be explained? One reason may be the difference in knowledge, experience, and evidence because the incidence rate of testicular cancer is more than 15 times that of ovarian GCTs. Given the rarity of the disease in women and the lack of established guidelines, a comprehensive understanding of the disease and treatment decisions is challenging. The main objective of this review is to derive insights from testicular GCTs (seminoma and non‐seminoma) by reviewing etiological, tumor biological, and clinical knowledge, and to thereafter suggest actions for ovarian GCTs based on this. We hypothesize that by adopting specific treatment strategies from testicular GCTs—including de‐escalating adjuvant chemotherapy for low‐risk patients and implementing more standardized and intensive treatment protocols in cases of relapse—we can improve the prognosis and minimize long‐term side effects in ovarian GCT patients.

show abstract

Adverse health outcomes and global quality of life in long-term testicular cancer survivors: a longitudinal 30-year perspective

Cited by 3 publications

References 53 publications

Assessing quality of life in childhood cancer survivors at risk for hearing loss: a comparison of HEAR-QL and PROMIS measures

Assessing quality of life in childhood cancer survivors at risk for hearing loss: a comparison of HEAR-QL and PROMIS measures

Favorable long-term Health Related Quality of Life in cured survivors of testicular cancer management. So, what now?

Malignant ovarian and testicular germ cell tumors: Common characteristics but different prognoses

Contact Info

Product

Resources

About